The Latest Breaking News from BMY

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth dip in the company’s bottom-line figure.

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

Although Bristol-Myers Squibb has outperformed the broader Nasdaq index over the past three months, analysts remain cautious about its growth prospects.

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Bristol-Myers has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.